16 – 17 year olds offered second dose of Covid vaccine.
The JCVI is advising that all 16 to 17-year-olds who are not in an at-risk group should be offered a second dose of the Pfizer vaccine. The second vaccine dose should be given 12 weeks or more following the first vaccine dose.
For those in this age group who have had COVID-19 infection, the second vaccine dose should be given 12 weeks or more following the first vaccine dose, or 12 weeks following a positive COVID-19 test result – whichever is later.
This advice is in addition to the existing offer of 2 doses of vaccine to 16 to 17-year-olds who are in ‘at-risk groups, as described in the Green Book.
The decision to advise the second dose is based on a review of the latest evidence of the benefits of the vaccine programme, compared to the risks of any side effects. A second vaccine dose increases the level of protection and is important for extending the duration of protection. As protection from the first dose will eventually start to decline, the benefits from the second vaccine dose will become more important over time. A second dose may also offer a reduction in the risk of hospitalisation and onward transmission to vulnerable close contacts.
In reports originating from outside the UK, extremely rare adverse reactions, such as myocarditis (inflammation of the heart) have been reported more frequently after the second vaccine dose compared to the first vaccine dose. However, in countries such as Canada and the UK, who have a longer interval between the first and second doses, rates following the second vaccine dose are closer to the reporting rate after the first dose.
The latest available data indicate that myocarditis following vaccination usually resolves within a short time, most cases respond well to treatment and where information is available, no major complications have been identified in the medium term (months).
Taking these factors into consideration, JCVI has concluded that the balance of risks and benefits supports offering a second dose of the Pfizer-BioNTech COVID-19 vaccine in persons aged 16 to 17 years who are not in an at-risk group.
Professor Wei Shen Lim, Chair, COVID-19 immunisation, JCVI said:
Booster vaccine doses in more vulnerable adults, and second vaccine doses in 16 to 17 year olds are important ways to increase our protection against COVID-19 infection and severe disease. These vaccinations will also help extend our protection into 2022.
“If you are eligible, please make sure to have these vaccines and keep yourselves protected as we head into winter.”